MANNKIND CORP (MNKD)
US56400P7069 - Common Stock
"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker
Our first-ever twin bill.
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
INHALE-3 STUDY REVEALS POSITIVE READOUT IN HEAD-TO-HEAD COMPARISON OF INHALED INSULIN VS. USUAL CARE IN T1D; NEW DATA PRESENTED...
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
INHALE-3 STUDY RESULTS TO BE PRESENTED DURING A 90-MINUTE SYMPOSIUM ON SATURDAY, JUNE 22 AT THE AMERICAN DIABETES ASSOCIATION’S 84TH SCIENTIFIC SESSIONS...
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
MANNKIND TO ESTABLISH BOSTON-AREA RESEARCH & DEVELOPMENT FOOTHOLD AND EXPAND PORTFOLIO OF DRY POWDER INHALATION TECHNOLOGY IN TRANSACTION WITH PULMATRIX...
MannKind (MNKD) Q1 2024 Earnings Call Transcript
MNKD earnings call for the period ending March 31, 2024.
MNKD Stock Earnings: MannKind Beats EPS, Beats Revenue for Q1 2024
MNKD stock results show that MannKind beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
Conference Call to Begin Today at 5:00 p.m. (ET)
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
Conference Call to Begin Today at 5:00 p.m. (ET)...
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
MANNKIND RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR CLOFAZIMINE INHALATION SUSPENSION FOR THE TREATMENT OF SERIOUS LUNG DISEASE...
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2024 first quarter...
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
MannKind announced it will proceed with a Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases including IPF. ...
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
MANNKIND ANNOUNCES IND CLEARANCE FROM U.S. FDA TO START PHASE 3 STUDY OF CLOFAZIMINE INHALATION SUSPENSION FOR NTM LUNG DISEASE...
MNKD Makes Notable Cross Below Critical Moving Average
MannKind Repays Certain Debt Obligations
MannKind Repays Certain Debt Obligations
Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 millionConvertible note issued to Mann Group LLC repaid in...
May 10th Options Now Available For MannKind (MNKD)
MannKind Announces CFO Transition
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
INHALE-3 STUDY’S INITIAL MEAL CHALLENGE RESULTS COMPARING AFREZZA® HEAD-TO-HEAD WITH MULTIPLE DAILY INJECTIONS (MDI) AND INSULIN PUMPS ...
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
Dr. Hirsch to present meal challenge results when switching from multiple daily injections (MDI) or insulin pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder)
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
Dr. Hirsch to present meal challenge results when switching from multiple daily injections (MDI) or insulin pumps to inhaled insulin (Afrezza® (insulin...
MannKind Corporation Announces Participation at Upcoming Conferences
MannKind Corporation Announces Participation at Upcoming Conferences
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development...
MannKind (MNKD) Q4 2023 Earnings Call Transcript
MNKD earnings call for the period ending December 31, 2023.
MannKind Non-GAAP EPS of $0.02 beats by $0.03, revenue of $58.47M beats by $5.33M (NASDAQ:MNKD)
MannKind Corporation's Q4 financial results exceeded expectations with non-GAAP EPS of $0.02, beating estimates by $0.03, and revenue of $58.47M, surpassing...
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
Conference Call to Begin Today at 5:00 p.m. (ET)
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
Conference Call to Begin Today at 5:00 p.m. (ET)...